Be DNA Certain your prostate biopsy belongs to you.
Did you know that up to 3.5%1 of prostate biopsy samples may be contaminated with specimens from another patient? And in the case of Biomarker Testing2 a specimen admixture (contaminated with another’s DNA) can cause incorrect findings and confound the biomarker results leading to erroneous therapy and adverse patient outcomes.
The biopsy evaluation process requires many steps and several medical professionals working at different locations. To help protect you from specimen contamination and transposition errors the patented know error® system confirms biopsy specimens are free from contamination and exclusively belong to the patient being evaluated.
As part of the routine biopsy process for prostate cancer your physician can request the know error® system for prostate biopsies. If you are diagnosed with cancer a DNA test will be used to match your reference swab (taken at the time of your biopsy) to your prostate biopsy tissue(s). You and your physician will then be able to move forward with a personalized treatment plan knowing you have eliminated any potential specimen contamination errors and that the cancer diagnosis is correctly ascribed to you.
The know error® system uses three simple steps to ensure that when you receive your prostate biopsy results they belong to you:
Your DNA sample is taken by gently swabbing the inside of your cheek at the time of your biopsy.
Your biopsy tissue sample(s) are placed in bar-coded specimen vials and sent to pathology for evaluation.
3. DNA Match
DNA Specimen Provenance Assay (DSPA), a DNA test, compares your (1) reference swab with the (2) cancerous biopsy tissue sample to ensure a (3) DNA match.
You and your physician can prevent inaccurate diagnosis due to biopsy specimen misidentification with the know error® system for prostate biopsies.
1. Pfeifer JD, Liu J. Rate of occult specimen provenance complications in routine clinical practice. Am J Clin Path. 2013;139(1):93-100.
2. Sehn JK, Spenser DH, Pfeifer JD, et al. Occult specimen contamination in routine clinical next-general sequencing testing. Am J Clin Path. Oct 2015;144:667-674.